Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$4.03+0.15 (+3.87%)
Close on Nov 12, 2026Market cap $797.33MP/E 3.6Yield –
Arbutus Biopharma price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Arbutus Biopharma's price to book ratio was 3.0× on Nov 11, 2026, against 10.9× a year earlier. Over the last 5 years it ranged from 1.9× to 11.9×, with a median of 3.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.0× | −9.0 |
| 2025 | Dec 31, 2025 | 11.9× | +6.1 |
| 2024 | Dec 31, 2024 | 5.8× | +2.3 |
| 2023 | Dec 29, 2023 | 3.5× | +1.1 |
| 2022 | Dec 30, 2022 | 2.4× | −0.9 |
| 2021 | Dec 31, 2021 | 3.3× | +0.2 |
| 2020 | Dec 31, 2020 | 3.1× | +1.2 |
| 2019 | Dec 31, 2019 | 1.9× | +0.9 |
| 2018 | Dec 31, 2018 | 1.0× | −0.7 |
| 2017 | Dec 29, 2017 | 1.7× | +1.3 |
| 2016 | Dec 30, 2016 | 0.3× | −0.1 |
| 2015 | Dec 31, 2015 | 0.4× | −3.1 |
| 2014 | Dec 31, 2014 | 3.5× | +0.7 |
| 2013 | Dec 31, 2013 | 2.8× | −8.7 |
| 2012 | Dec 31, 2012 | 11.5× | +10.1 |
| 2011 | Dec 30, 2011 | 1.4× | – |
See a number that looks wrong?